Personalized cancer treatment via targeted therapies is two-to-three times more effective than standard chemotherapy for patients with advanced or metastatic cancer. But for patients to benefit, they must have access to robust biomarker testing capabilities, a challenge in many community cancer settings. Yet this testing is time-consuming and costly to outsource.


The solution? Canexia Health can help your lab deploy cancer genomics assays at a fraction of the cost of outsourcing multigene panels to a centralized lab, and without the need to invest in a costly bioinformatics infrastructure. 


Our Clinical Services team supports labs with bringing precision oncology programs in-house, including the implementation and maintenance of clinical next-generation sequencing-based profiling.


Watch our video to learn how we can help you deliver on your mandate for providing best-in-class cancer care.


Recent Resources


August 30, 2022

CGC 2022 Key Takeaways

NGS Reporting, Whole Genome Sequencing, and In-House Testing major themes in this year’s meeting